ABVC BioPharma (NASDAQ:ABVC) Announces Earnings Results, Beats Expectations By $0.36 EPS

ABVC BioPharma (NASDAQ:ABVC) released its quarterly earnings results on Tuesday. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.36, FiscalAI reports.

ABVC BioPharma Price Performance

Shares of NASDAQ ABVC traded down $0.03 during midday trading on Tuesday, hitting $0.99. The stock had a trading volume of 34,952 shares, compared to its average volume of 100,511. The firm has a market cap of $26.42 million, a P/E ratio of -3.30 and a beta of 0.47. ABVC BioPharma has a fifty-two week low of $0.71 and a fifty-two week high of $3.06. The company’s 50-day simple moving average is $1.01 and its 200 day simple moving average is $1.23.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a report on Friday, September 11th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, the company has an average rating of “Sell”.

ABVC BioPharma Company Profile

ABVC BioPharma, Inc. (NASDAQ: ABVC) is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and oncology-related conditions, as well as certain medical devices. The company advances product candidates through preclinical and clinical development and works with research, development and commercialization partners. ABVC’s pipeline has included investigational therapies for major depressive disorder and other central nervous system conditions, along with oncology programs targeting cancer treatment.